{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T22:21:30Z","timestamp":1794262890610,"version":"4.9.0"},"reference-count":125,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Neurofibromatosis Type 1 (NF1), an autosomal dominant genetic disorder, is characterized by extensive clinical variability, posing significant challenges for prognosis and patient management. Despite being caused by mutations in a single gene,\n                    <jats:italic>NF1<\/jats:italic>\n                    , the expressivity of the disease ranges from mild cutaneous manifestations to severe, life-threatening complications, including malignant tumors, skeletal deformities, and cognitive impairments. This paper provides a comprehensive review of the genetic determinants underlying this phenotypic heterogeneity. We begin by elucidating the molecular genetics of NF1, detailing the structure and function of the\n                    <jats:italic>NF1<\/jats:italic>\n                    gene and its protein product, neurofibromin, and the diverse spectrum of mutations that cause the disorder. Neurofibromin\u2019s critical role as a negative regulator of the Ras signaling pathway is central to understanding the pathophysiology of NF1. Subsequently, the paper explores the primary mechanisms driving phenotypic variation, including established genotype-phenotype correlations, the influence of genetic modifiers, the impact of somatic mosaicism and second-hit mutations, and the emerging role of epigenetic and environmental factors. By synthesizing current knowledge, this review aims to construct a holistic view of the complex interplay between the primary\n                    <jats:italic>NF1<\/jats:italic>\n                    mutation and the broader genetic landscape that ultimately shapes the clinical presentation of NF1. Understanding these determinants is crucial for advancing diagnostic capabilities, developing personalized therapeutic strategies, and improving clinical outcomes for individuals affected by this complex disorder.\n                  <\/jats:p>","DOI":"10.1186\/s13023-026-04334-1","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T10:34:21Z","timestamp":1776249261000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Genetic and non-genetic factors influencing phenotypic variability in neurofibromatosis type 1"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4213-4053","authenticated-orcid":false,"given":"Patricia Bianca","family":"Clissa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8876-8262","authenticated-orcid":false,"given":"Sabri Saeed","family":"Sanabani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"4334_CR1","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/ajmg.a.33139","volume":"152A","author":"DG Evans","year":"2010","unstructured":"Evans DG, Howard E, Giblin C, Clancy T, Spencer H, Huson SM, et al. Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A. 2010;152A:327\u201332.","journal-title":"Am J Med Genet A"},{"key":"4334_CR2","doi-asserted-by":"crossref","unstructured":"Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. (1988): 575\u201378. Arch Neurol 45.","DOI":"10.1001\/archneur.1988.00520290115023"},{"key":"4334_CR3","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/gim.2018.28","volume":"20","author":"DR Stewart","year":"2018","unstructured":"Stewart DR, Korf BR, Nathanson KL, Stevenson DA, Yohay K. Care of adults with neurofibromatosis type 1: a clinical practice resource of the American College of Medical genetics and Genomics (ACMG). Genet Med. 2018;20:671\u201382.","journal-title":"Genet Med"},{"key":"4334_CR4","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1080\/14737175.2024.2324117","volume":"24","author":"N Kerashvili","year":"2024","unstructured":"Kerashvili N, Gutmann DH. The management of neurofibromatosis type 1 (NF1) in children and adolescents. Expert Rev Neurother. 2024;24:409\u201320.","journal-title":"Expert Rev Neurother"},{"key":"4334_CR5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/j.1749-6632.1986.tb48061.x","volume":"486","author":"JC Carey","year":"1986","unstructured":"Carey JC, Baty BJ, Johnson JP, Morrison T, Skolnick M, Kivlin J. The genetic aspects of neurofibromatosis. Ann N Y Acad Sci. 1986;486:45\u201356.","journal-title":"Ann N Y Acad Sci"},{"key":"4334_CR6","first-page":"305","volume":"53","author":"DF Easton","year":"1993","unstructured":"Easton DF, Ponder MA, Huson SM, Ponder BA. An analysis of variation in expression of neurofibromatosis (NF) type 1 (NF1): evidence for modifying genes. Am J Hum Genet. 1993;53:305\u201313.","journal-title":"Am J Hum Genet"},{"key":"4334_CR7","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1136\/jmedgenet-2012-100978","volume":"49","author":"E Pasmant","year":"2012","unstructured":"Pasmant E, Vidaud M, Vidaud D, Wolkenstein P. Neurofibromatosis type 1: from genotype to phenotype. J Med Genet. 2012;49:483\u201389.","journal-title":"J Med Genet"},{"key":"4334_CR8","doi-asserted-by":"publisher","first-page":"991314","DOI":"10.3389\/fgene.2022.991314","volume":"13","author":"J Xu","year":"2022","unstructured":"Xu J, Zhang Y, Zhu K, Li J, Guan Y, He X, et al. Clinical characteristics and in silico analysis of congenital pseudarthrosis of the tibia combined with neurofibromatosis type 1 caused by a novel NF1 mutation. Front Genet. 2022;13:991314.","journal-title":"Front Genet"},{"key":"4334_CR9","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1126\/science.3107130","volume":"236","author":"D Barker","year":"1987","unstructured":"Barker D, Wright E, Nguyen K, Cannon L, Fain P, Goldgar D, et al. Gene for von recklinghausen neurofibromatosis is in the pericentromeric region of chromosome 17. Science. 1987;236:1100\u201302.","journal-title":"Science"},{"key":"4334_CR10","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/0092-8674(90)90252-A","volume":"62","author":"D Viskochil","year":"1990","unstructured":"Viskochil D, Buchberg AM, Xu G, Cawthon RM, Stevens J, Wolff RK, et al. Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell. 1990;62:187\u201392.","journal-title":"Cell"},{"key":"4334_CR11","doi-asserted-by":"publisher","first-page":"9658","DOI":"10.1073\/pnas.88.21.9658","volume":"88","author":"DH Gutmann","year":"1991","unstructured":"Gutmann DH, Wood DL, Collins FS. Identification of the neurofibromatosis type 1 gene product. Proc Natl Acad Sci U S A. 1991;88:9658\u201362.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4334_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/0888-7543(95)80104-T","volume":"25","author":"Y Li","year":"1995","unstructured":"Li Y, O\u2019Connell P, Breidenbach HH, Cawthon R, Stevens J, Xu G, et al. Genomic organization of the neurofibromatosis 1 gene (NF1). Genomics. 1995;25:9\u201318.","journal-title":"Genomics"},{"key":"4334_CR13","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/978-3-642-32864-0_12","volume-title":"Neurofibromatosis type, 1: molecular and cellular biology","author":"L Messiaen","year":"2012","unstructured":"Messiaen L, Xie J. NF1 germline and somatic mosaicism. In: Upadhyaya M, Cooper DN, editors. Neurofibromatosis type, 1: molecular and cellular biology. Berlin Heidelberg, Berlin, Heidelberg: Springer; 2012. p. 151\u201372."},{"key":"4334_CR14","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/0888-7543(91)90017-9","volume":"11","author":"DA Marchuk","year":"1991","unstructured":"Marchuk DA, Saulino AM, Tavakkol R, Swaroop M, Wallace MR, Andersen LB, et al. cDNA cloning of the type 1 neurofibromatosis gene: complete sequence of the NF1 gene product. Genomics. 1991;11:931\u201340.","journal-title":"Genomics"},{"key":"4334_CR15","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/0896-6273(92)90270-N","volume":"8","author":"MM Daston","year":"1992","unstructured":"Daston MM, Scrable H, Nordlund M, Sturbaum AK, Nissen LM, Ratner N. The protein product of the neurofibromatosis type 1 gene is expressed at highest abundance in neurons, Schwann cells, and oligodendrocytes. Neuron. 1992;8:415\u201328.","journal-title":"Neuron"},{"key":"4334_CR16","doi-asserted-by":"crossref","unstructured":"Bergoug M, Doudeau M, Godin F, Mosrin C, Vallee B, Benedetti H. Neurofibromin structure, functions and regulation. Cells. 2020;9.","DOI":"10.3390\/cells9112365"},{"key":"4334_CR17","doi-asserted-by":"crossref","unstructured":"Chaker-Margot M, Werten S, Dunzendorfer-Matt T, Lechner S, Ruepp A, Scheffzek K, et al. Structural basis of activation of the tumor suppressor protein neurofibromin. Mol Cell. 2022;82:1288-+.","DOI":"10.1016\/j.molcel.2022.03.011"},{"key":"4334_CR18","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/0092-8674(90)90024-9","volume":"62","author":"GF Xu","year":"1990","unstructured":"Xu GF, O\u2019Connell P, Viskochil D, Cawthon R, Robertson M, Culver M, et al. The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell. 1990;62:599\u2013608.","journal-title":"Cell"},{"key":"4334_CR19","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.4049\/jimmunol.178.4.2527","volume":"178","author":"WF Khalaf","year":"2007","unstructured":"Khalaf WF, Yang FC, Chen S, White H, Bessler W, Ingram DA, et al. K-ras is critical for modulating multiple c-kit-mediated cellular functions in wild-type and Nf1\u00b1 mast cells. J Immunol. 2007;178:2527\u201334.","journal-title":"J Immunol"},{"key":"4334_CR20","doi-asserted-by":"publisher","first-page":"252","DOI":"10.4274\/balkanmedj.galenos.2023.2022-12-28","volume":"40","author":"M Gjorgjievska","year":"2023","unstructured":"Gjorgjievska M, Bozhinovski G, Sukarova-Angelovska E, Kocova M, Kanzoska LM, Plaseska-Karanfilska D. Mutational spectrum and genotype-phenotype correlations in neurofibromatosis type 1 patients from North Macedonia: identification of ten novel NF1 pathogenic variants. Balkan Med J. 2023;40:252\u201361.","journal-title":"Balkan Med J"},{"key":"4334_CR21","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical genetics and Genomics and the association for molecular Pathology. Genet Med. 2015;17:405\u201324.","journal-title":"Genet Med"},{"key":"4334_CR22","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1093\/hmg\/4.6.975","volume":"4","author":"RA Heim","year":"1995","unstructured":"Heim RA, Kam-Morgan LN, Binnie CG, Corns DD, Cayouette MC, Farber RA, et al. Distribution of 13 truncating mutations in the neurofibromatosis 1 gene. Hum Mol Genet. 1995;4:975\u201381.","journal-title":"Hum Mol Genet"},{"key":"4334_CR23","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/1098-1004(200006)15:6<541::AID-HUMU6>3.0.CO;2-N","volume":"15","author":"LM Messiaen","year":"2000","unstructured":"Messiaen LM, Callens T, Mortier G, Beysen D, Vandenbroucke I, Van Roy N, et al. Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects. Hum Mutat. 2000;15:541\u201355.","journal-title":"Hum Mutat"},{"key":"4334_CR24","doi-asserted-by":"publisher","first-page":"4313","DOI":"10.1093\/emboj\/17.15.4313","volume":"17","author":"K Scheffzek","year":"1998","unstructured":"Scheffzek K, Ahmadian MR, Wiesm\u00fcller L, Kabsch W, Stege P, Schmitz F, et al. Structural analysis of the GAP-related domain from neurofibromin and its implications. Embo J. 1998;17:4313\u201327.","journal-title":"Embo J"},{"key":"4334_CR25","doi-asserted-by":"crossref","unstructured":"Xu L, Jang H, Nussinov R. Allosteric modulation of NF1 GAP: differential distributions of catalytically competent populations in loss-of-function and gain-of-function mutants. Protein Sci. 2025;34:e70042.","DOI":"10.1002\/pro.70042"},{"key":"4334_CR26","doi-asserted-by":"crossref","unstructured":"Pacot L, Vidaud D, Sabbagh A, Laurendeau I, Briand-Suleau A, Coustier A, et al. N. Members The Nf Fr, P. Wolkenstein, and E. Pasmant, Severe Phenotype in Patients with Large Deletions of NF1. Cancers (Basel) 2021;13.","DOI":"10.3390\/cancers13122963"},{"key":"4334_CR27","doi-asserted-by":"publisher","first-page":"673025","DOI":"10.3389\/fgene.2021.673025","volume":"12","author":"G Buki","year":"2021","unstructured":"Buki G, Zsigmond A, Czako M, Szalai R, Antal G, Farkas V, et al. Genotype-phenotype associations in patients with type-1, type-2, and atypical NF1 microdeletions. Front Genet. 2021;12:673025.","journal-title":"Front Genet"},{"key":"4334_CR28","doi-asserted-by":"publisher","first-page":"101227","DOI":"10.1016\/j.gim.2024.101227","volume":"27","author":"S Goh","year":"2025","unstructured":"Goh S, Thiyagarajan L, Dudding-Byth T, Pinese M, Kirk EP. A systematic review and pooled analysis of penetrance estimates of copy-number variants associated with neurodevelopment. Genet Med. 2025;27:101227.","journal-title":"Genet Med"},{"key":"4334_CR29","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1002\/humu.22692","volume":"35","author":"H Kehrer-Sawatzki","year":"2014","unstructured":"Kehrer-Sawatzki H, Bengesser K, Callens T, Mikhail F, Fu C, Hillmer M, et al. Identification of large NF1 duplications reciprocal to NAHR-mediated type-1 NF1 deletions. Hum Mutat. 2014;35:1469\u201375.","journal-title":"Hum Mutat"},{"key":"4334_CR30","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/s42003-023-04815-0","volume":"6","author":"J Baez-Flores","year":"2023","unstructured":"Baez-Flores J, Rodriguez-Martin M, Lacal J. The therapeutic potential of neurofibromin signaling pathways and binding partners. Commun Biol. 2023;6:436.","journal-title":"Commun Biol"},{"key":"4334_CR31","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1093\/jnen\/59.9.759","volume":"59","author":"N Lau","year":"2000","unstructured":"Lau N, Feldkamp MM, Roncari L, Loehr AH, Shannon P, Gutmann DH, et al. Loss of neurofibromin is associated with activation of RAS\/MAPK and PI3-K\/AKT signaling in a neurofibromatosis 1 astrocytoma. J Neuropathol Exp Neurol. 2000;59:759\u201367.","journal-title":"J Neuropathol Exp Neurol"},{"key":"4334_CR32","doi-asserted-by":"crossref","unstructured":"Anastasaki C, Orozco P, Gutmann DH. RAS and beyond: the many faces of the neurofibromatosis type 1 protein. Dis Model Mech. 2022;15.","DOI":"10.1242\/dmm.049362"},{"key":"4334_CR33","doi-asserted-by":"publisher","first-page":"5579","DOI":"10.1523\/JNEUROSCI.3994-09.2010","volume":"30","author":"JA Brown","year":"2010","unstructured":"Brown JA, Gianino SM, Gutmann DH. Defective cAMP generation underlies the sensitivity of CNS neurons to neurofibromatosis-1 heterozygosity. J Neurosci. 2010;30:5579\u201389.","journal-title":"J Neurosci"},{"key":"4334_CR34","doi-asserted-by":"crossref","unstructured":"Mazuelas H, Magallon-Lorenz M, Uriarte-Arrazola I, Negro A, Rosas I, Blanco I, et al. Unbalancing cAMP and Ras\/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas. JCI Insight. 2024;9.","DOI":"10.1172\/jci.insight.168826"},{"key":"4334_CR35","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.celrep.2014.07.054","volume":"8","author":"MA Wolman","year":"2014","unstructured":"Wolman MA, de Groh ED, McBride SM, Jongens TA, Granato M, Epstein JA. Modulation of cAMP and ras signaling pathways improves distinct behavioral deficits in a zebrafish model of neurofibromatosis type 1. Cell Rep. 2014;8:1265\u201370.","journal-title":"Cell Rep"},{"key":"4334_CR36","doi-asserted-by":"crossref","unstructured":"Sutton LP, Muntean BS, Ostrovskaya O, Zucca S, Dao M, Orlandi C, et al. NF1-cAMP signaling dissociates cell type-specific contributions of striatal medium spiny neurons to reward valuation and motor control. PLoS Biol. 2019;17:e3000477.","DOI":"10.1371\/journal.pbio.3000477"},{"key":"4334_CR37","doi-asserted-by":"publisher","first-page":"15996","DOI":"10.1073\/pnas.1019012108","volume":"108","author":"S Banerjee","year":"2011","unstructured":"Banerjee S, Crouse NR, Emnett RJ, Gianino SM, Gutmann DH. Neurofibromatosis-1 regulates mTOR-mediated astrocyte growth and glioma formation in a TSC\/Rheb-independent manner. Proc Natl Acad Sci U S A. 2011;108:15996\u20136001.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4334_CR38","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1074\/mcp.M116.064543","volume":"16","author":"X Li","year":"2017","unstructured":"Li X, Gao M, Choi JM, Kim BJ, Zhou MT, Chen Z, et al. Clustered, regularly interspaced short palindromic repeats (CRISPR)\/Cas9-coupled affinity Purification\/Mass spectrometry analysis revealed a novel role of neurofibromin in mTOR signaling. Mol Cell Proteomics. 2017;16:594\u2013607.","journal-title":"Mol Cell Proteomics"},{"key":"4334_CR39","doi-asserted-by":"crossref","unstructured":"Pasmant E, Sabbagh A, Spurlock G, Laurendeau I, Grillo E, Hamel MJ, et al. Vidaud, and N.F.F.N. members of the, NF1 microdeletions in neurofibromatosis type 1: from genotype to phenotype. Hum Mutat. 2010;31:E1506\u201318.","DOI":"10.1002\/humu.21271"},{"key":"4334_CR40","doi-asserted-by":"publisher","first-page":"738300","DOI":"10.3389\/fonc.2021.738300","volume":"11","author":"W Li","year":"2021","unstructured":"Li W, Hu C, Zhang X, Wang B, Li Z, Ling M, et al. SUZ12 loss amplifies the Ras\/ERK pathway by activating adenylate cyclase 1 in NF1-associated neurofibromas. Front Oncol. 2021;11:738300.","journal-title":"Front Oncol"},{"key":"4334_CR41","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1158\/2159-8290.CD-22-0786","volume":"13","author":"I Cortes-Ciriano","year":"2023","unstructured":"Cortes-Ciriano I, Steele CD, Piculell K, Al-Ibraheemi A, Eulo V, Bui MM, et al. Genomics of, genomic patterns of malignant peripheral nerve sheath tumor (MPNST) evolution correlate with clinical outcome and are detectable in cell-free DNA. Cancer Discov. 2023;13:654\u201371.","journal-title":"Cancer Discov"},{"key":"4334_CR42","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1086\/374821","volume":"72","author":"T De Raedt","year":"2003","unstructured":"De Raedt T, Brems H, Wolkenstein P, Vidaud D, Pilotti S, Perrone F, et al. Elevated risk for MPNST in NF1 microdeletion patients. Am J Hum Genet. 2003;72:1288\u201392.","journal-title":"Am J Hum Genet"},{"key":"4334_CR43","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1086\/510781","volume":"80","author":"M Upadhyaya","year":"2007","unstructured":"Upadhyaya M, Huson SM, Davies M, Thomas N, Chuzhanova N, Giovannini S, et al. An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in exon 17 of the NF1 gene (c.2970-2972 delAAT): evidence of a clinically significant NF1 genotype-phenotype correlation. Am J Hum Genet. 2007;80:140\u201351.","journal-title":"Am J Hum Genet"},{"key":"4334_CR44","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ajhg.2017.12.001","volume":"102","author":"M Koczkowska","year":"2018","unstructured":"Koczkowska M, Chen Y, Callens T, Gomes A, Sharp A, Johnson S, et al. Genotype-phenotype correlation in NF1: evidence for a more severe phenotype associated with missense mutations affecting NF1 codons 844-848. Am J Hum Genet. 2018;102:69\u201387.","journal-title":"Am J Hum Genet"},{"key":"4334_CR45","doi-asserted-by":"crossref","unstructured":"Pacot L, Blok M, Vidaud D, Fertitta L, Laurendeau I, Coustier A, et al. Refined genotype-phenotype correlations in neurofibromatosis type 1 patients with NF1 point variants. J Med Genet. 2025.","DOI":"10.1136\/jmg-2025-110783"},{"key":"4334_CR46","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1002\/humu.22392","volume":"34","author":"A Sabbagh","year":"2013","unstructured":"Sabbagh A, Pasmant E, Imbard A, Luscan A, Soares M, Blanche H, et al. NF1 molecular characterization and neurofibromatosis type I genotype-phenotype correlation: the French experience. Hum Mutat. 2013;34:1510\u201318.","journal-title":"Hum Mutat"},{"key":"4334_CR47","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/humu.10215","volume":"21","author":"A Colosimo","year":"2003","unstructured":"Colosimo A, Guida V, Rigoli L, Di Bella C, De Luca A, Briuglia S, et al. Molecular detection of novel WFS1 mutations in patients with wolfram syndrome by a DHPLC-based assay. Hum Mutat. 2003;21:622\u201329.","journal-title":"Hum Mutat"},{"key":"4334_CR48","doi-asserted-by":"crossref","unstructured":"Bettegowda C, Upadhayaya M, Evans DG, Kim A, Mathios D, Hanemann CO, et al. Genotype-phenotype correlations in neurofibromatosis and their potential clinical use. Neurology. 2021;97:S91\u201398.","DOI":"10.1212\/WNL.0000000000012436"},{"key":"4334_CR49","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/01677063.2018.1456538","volume":"32","author":"P Sharafi","year":"2018","unstructured":"Sharafi P, Ayter S. Possible modifier genes in the variation of neurofibromatosis type 1 clinical phenotypes. J Neurogenet. 2018;32:65\u201377.","journal-title":"J Neurogenet"},{"key":"4334_CR50","doi-asserted-by":"crossref","unstructured":"Woycinck Kowalski T, Brussa Reis L, Finger Andreis T, Ashton-Prolla P, Rosset C. Systems Biology approaches reveal potential phenotype-modifier genes in neurofibromatosis type 1. Cancers (Basel). 2020;12.","DOI":"10.3390\/cancers12092416"},{"key":"4334_CR51","doi-asserted-by":"crossref","unstructured":"Tang J, Li N, Li G, Wang J, Yu T, Yao R. Assessment of rare genetic variants to identify candidate modifier genes underlying neurological manifestations in neurofibromatosis 1 patients. Genes (Basel). 2022;13.","DOI":"10.21203\/rs.3.rs-2012218\/v1"},{"key":"4334_CR52","doi-asserted-by":"crossref","unstructured":"Pemov A, Sung H, Hyland PL, Sloan JL, Ruppert SL, Baldwin AM, et al. Genetic modifiers of neurofibromatosis type 1-associated cafe-au-lait macule count identified using multi-platform analysis. PLoS Genet. 2014;10:e1004575.","DOI":"10.1371\/journal.pgen.1004575"},{"key":"4334_CR53","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1093\/bjd\/ljad390","volume":"190","author":"L Pacot","year":"2024","unstructured":"Pacot L, Sabbagh A, Sohier P, Hadjadj D, Ye M, Boland-Auge A, et al. Identification of potential common genetic modifiers of neurofibromas: a genome-wide association study in 1333 patients with neurofibromatosis type 1. Br J Dermatol. 2024;190:226\u201343.","journal-title":"Br J Dermatol"},{"key":"4334_CR54","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/1471-2350-13-98","volume":"13","author":"T Mussotter","year":"2012","unstructured":"Mussotter T, Kluwe L, Hogel J, Nguyen R, Cooper DN, Mautner VF, et al. Non-coding RNA ANRIL and the number of plexiform neurofibromas in patients with NF1 microdeletions. BMC Med Genet. 2012;13:98.","journal-title":"BMC Med Genet"},{"key":"4334_CR55","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/hmg\/ddp212","volume":"18","author":"A Sabbagh","year":"2009","unstructured":"Sabbagh A, Pasmant E, Laurendeau I, Parfait B, Barbarot S, Guillot B, et al. Unravelling the genetic basis of variable clinical expression in neurofibromatosis 1. Hum Mol Genet. 2009;18:2768\u201378.","journal-title":"Hum Mol Genet"},{"key":"4334_CR56","doi-asserted-by":"publisher","first-page":"704639","DOI":"10.3389\/fneur.2021.704639","volume":"12","author":"W Wang","year":"2021","unstructured":"Wang W, Wei CJ, Cui XW, Li YH, Gu YH, Gu B, et al. Impacts of NF1 gene mutations and genetic modifiers in neurofibromatosis type 1. Front Neurol. 2021;12:704639.","journal-title":"Front Neurol"},{"key":"4334_CR57","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1086\/515504","volume":"61","author":"E Serra","year":"1997","unstructured":"Serra E, Puig S, Otero D, Gaona A, Kruyer H, Ars E, et al. Confirmation of a double-hit model for the NF1 gene in benign neurofibromas. Am J Hum Genet. 1997;61:512\u201319.","journal-title":"Am J Hum Genet"},{"key":"4334_CR58","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/cas.13116","volume":"108","author":"O Hino","year":"2017","unstructured":"Hino O, Kobayashi T. Knudson, mourning dr. Alfred G. The two-hit hypothesis, tumor suppressor genes, and the tuberous sclerosis complex. Cancer Sci. 2017;108:5\u201311.","journal-title":"Cancer Sci"},{"key":"4334_CR59","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1073\/pnas.68.4.820","volume":"68","author":"AG Knudson, Jr","year":"1971","unstructured":"Knudson, Jr AG. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A. 1971;68:820\u201323.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4334_CR60","doi-asserted-by":"crossref","unstructured":"Gottfried ON, Viskochil DH, Couldwell WT. Neurofibromatosis type 1 and tumorigenesis: molecular mechanisms and therapeutic implications. Neurosurg Focus. 2010;28:E8.","DOI":"10.3171\/2009.11.FOCUS09221"},{"key":"4334_CR61","doi-asserted-by":"crossref","unstructured":"Yu X, Gu Y, Liu J, Huang J, Li Q, Wang Z. Emerging mechanism and therapeutic potential of neurofibromatosis type 1-related nerve system tumor: advancing insights into tumor development. Neurooncol Adv. 2025;7(vdaf 040).","DOI":"10.1093\/noajnl\/vdaf040"},{"key":"4334_CR62","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41588-025-02097-2","volume":"57","author":"TRW Oliver","year":"2025","unstructured":"Oliver TRW, Lawson ARJ, Lee-Six H, Tollit A, Jung H, Hooks Y, et al. Cancer-independent somatic mutation of the wild-type NF1 allele in normal tissues in neurofibromatosis type 1. Nat Genet. 2025;57:515\u201321.","journal-title":"Nat Genet"},{"key":"4334_CR63","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1038\/s41467-025-57077-1","volume":"16","author":"A Safonov","year":"2025","unstructured":"Safonov A, Nomakuchi TT, Chao E, Horton C, Dolinsky JS, Yussuf A, et al. A genotype-first approach identifies high incidence of NF1 pathogenic variants with distinct disease associations. Nat Commun. 2025;16:3121.","journal-title":"Nat Commun"},{"key":"4334_CR64","unstructured":"Friedman JM. Neurofibromatosis 1. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews((R)). Seattle (WA); 1993."},{"key":"4334_CR65","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s00439-021-02410-z","volume":"141","author":"H Kehrer-Sawatzki","year":"2022","unstructured":"Kehrer-Sawatzki H, Cooper DN. Challenges in the diagnosis of neurofibromatosis type 1 (NF1) in young children facilitated by means of revised diagnostic criteria including genetic testing for pathogenic NF1 gene variants. Hum Genet. 2022;141:177\u201391.","journal-title":"Hum Genet"},{"key":"4334_CR66","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s13402-025-01054-9","volume":"48","author":"Y Yu","year":"2025","unstructured":"Yu Y, Wei C, Yue M, Zhang C, Wang Y, Wang Z. From benign neurofibromas to malignant peripheral nerve sheath tumors (MPNST): a gaming among multiple factors. Cell Oncol (Dordr). 2025;48:841\u201357.","journal-title":"Cell Oncol (Dordr)"},{"key":"4334_CR67","doi-asserted-by":"crossref","unstructured":"Hirbe AC, Dehner CA, Dombi E, Eulo V, Gross AM, Sundby T, et al. Contemporary approach to neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Am Soc Clin Oncol Educ Book. 2024;44:e432242.","DOI":"10.1200\/EDBK_432242"},{"key":"4334_CR68","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s004390000322","volume":"107","author":"MP Horan","year":"2000","unstructured":"Horan MP, Cooper DN, Upadhyaya M. Hypermethylation of the neurofibromatosis type 1 (NF1) gene promoter is not a common event in the inactivation of the NF1 gene in NF1-specific tumours. Hum Genet. 2000;107:33\u201339.","journal-title":"Hum Genet"},{"key":"4334_CR69","doi-asserted-by":"crossref","unstructured":"Stylianides C, Hadjigavriel G, Theotokis P, Vakirlis E, Meditskou S, Manthou ME, et al. Epigenetic mechanisms in neurofibromatosis types 1 and 2. Epigenomes. 2025;9.","DOI":"10.3390\/epigenomes9030030"},{"key":"4334_CR70","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1111\/j.1349-7006.2010.01616.x","volume":"101","author":"GL Chai","year":"2010","unstructured":"Chai GL, Liu N, Ma JR, Li H, Oblinger JL, Prahalad AK, et al. MicroRNA-10b regulates tumorigenesis in neurofibromatosis type 1. Cancer Sci. 2010;101:1997\u20132004.","journal-title":"Cancer Sci"},{"key":"4334_CR71","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/1479-7364-6-23","volume":"6","author":"A Sedani","year":"2012","unstructured":"Sedani A, Cooper DN, Upadhyaya M. An emerging role for microRNAs in NF1 tumorigenesis. Hum Genomics. 2012;6:23.","journal-title":"Hum Genomics"},{"key":"4334_CR72","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1016\/j.jid.2022.12.027","volume":"143","author":"C Jiang","year":"2023","unstructured":"Jiang C, McKay RM, Lee SY, Romo CG, Blakeley JO, Haniffa M, et al. Cutaneous neurofibroma heterogeneity: factors that influence tumor burden in neurofibromatosis type 1. J Invest Dermatol. 2023;143:1369\u201377.","journal-title":"The J Invest Dermatol"},{"key":"4334_CR73","doi-asserted-by":"publisher","first-page":"104785","DOI":"10.18632\/oncotarget.18975","volume":"8","author":"Z Yuan","year":"2017","unstructured":"Yuan Z, Xu L, Zhao Z, Xu S, Zhang X, Liu T, et al. Clinicopathological features and prognosis of malignant peripheral nerve sheath tumor: a retrospective study of 159 cases from 1999 to 2016. Oncotarget. 2017;8:104785\u201395.","journal-title":"Oncotarget"},{"key":"4334_CR74","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1215\/15228517-2008-127","volume":"11","author":"HR Brekke","year":"2009","unstructured":"Brekke HR, Kolberg M, Skotheim RI, Hall KS, Bjerkehagen B, Risberg B, et al. Identification of p53 as a strong predictor of survival for patients with malignant peripheral nerve sheath tumors. Neuro Oncol. 2009;11:514\u201328.","journal-title":"Neuro Oncol"},{"key":"4334_CR75","doi-asserted-by":"crossref","unstructured":"Darrigo Junior LG, Ferraz VEF, Cormedi MCV, Araujo LHH, Magalhaes MPS, Carneiro RC, et al. Epidemiological profile and clinical characteristics of 491 Brazilian patients with neurofibromatosis type 1. Brain Behav. 2022;12:e 2599.","DOI":"10.1002\/brb3.2599"},{"key":"4334_CR76","doi-asserted-by":"publisher","first-page":"886697","DOI":"10.3389\/fsurg.2022.886697","volume":"9","author":"LN Lohkamp","year":"2022","unstructured":"Lohkamp LN, Parkin P, Puran A, Bartels UK, Bouffet E, Tabori U, et al. Optic pathway glioma in children with neurofibromatosis type, 1: a Multidisciplinary entity, posing dilemmas in diagnosis and management Multidisciplinary management of optic pathway glioma in children with neurofibromatosis type 1. Front Surg. 2022;9:886697.","journal-title":"Front Surg"},{"key":"4334_CR77","doi-asserted-by":"publisher","first-page":"918136","DOI":"10.3389\/fped.2022.918136","volume":"10","author":"H Li","year":"2022","unstructured":"Li H, Zhang W, Yao Z, Guo R, Hao C, Zhang X. Genotypes and clinical intervention of patients with neurofibromatosis type 1 associated dystrophic scoliosis. Front Pediatr. 2022;10:918136.","journal-title":"Front. Pediatr"},{"key":"4334_CR78","doi-asserted-by":"crossref","unstructured":"Pimentel MF, Heath A, Wan MJ, Hussein R, Leahy KE, MacDonald H, et al. Prevalence of choroidal abnormalities and lisch nodules in children meeting clinical and molecular diagnosis of neurofibromatosis type 1. Transl Vis Sci Technol. 2022) 10 11.","DOI":"10.1167\/tvst.11.2.10"},{"key":"4334_CR79","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.1172\/JCI99424","volume":"128","author":"CP Liao","year":"2018","unstructured":"Liao CP, Booker RC, Brosseau JP, Chen Z, Mo J, Tchegnon E, et al. Contributions of inflammation and tumor microenvironment to neurofibroma tumorigenesis. J Clin Invest. 2018;128:2848\u201361.","journal-title":"J. Clin. Invest"},{"key":"4334_CR80","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1093\/neuonc\/noaa153","volume":"23","author":"AA Azizi","year":"2021","unstructured":"Azizi AA, Walker DA, Liu JF, Sehested A, Jaspan T, Pemp B, et al. Siope Nf1 Opg Nottingham, NF1 optic pathway glioma: analyzing risk factors for visual outcome and indications to treat. Neuro Oncol. 2021;23:100\u201311.","journal-title":"Neuro Oncol"},{"key":"4334_CR81","doi-asserted-by":"publisher","first-page":"667","DOI":"10.2147\/CMAR.S362678","volume":"15","author":"Y Tang","year":"2023","unstructured":"Tang Y, Gutmann DH. Neurofibromatosis type 1-associated optic pathway gliomas: current challenges and future prospects. Cancer Manag Res. 2023;15:667\u201381.","journal-title":"Cancer Manag Res"},{"key":"4334_CR82","unstructured":"Huang M, Patel J, Gasalberti DP, Patel BC. Optic nerve glioma, StatPearls, treasure Island (FL), 2025."},{"key":"4334_CR83","doi-asserted-by":"publisher","first-page":"227","DOI":"10.3389\/fped.2017.00227","volume":"5","author":"MM Torres Nupan","year":"2017","unstructured":"Torres Nupan MM, Velez Van Meerbeke A, Lopez Cabra CA, Herrera Gomez PM. Cognitive and behavioral disorders in children with neurofibromatosis type 1. Front Pediatr. 2017;5:227.","journal-title":"Front. Pediatr"},{"key":"4334_CR84","first-page":"973","volume":"48","author":"SL Hyman","year":"2006","unstructured":"Hyman SL, Arthur Shores E, North KN. Learning disabilities in children with neurofibromatosis type 1: subtypes, cognitive profile, and attention-deficit-hyperactivity disorder. Dev Med Child Neurol. 2006;48:973\u201377.","journal-title":"Dev Med Child Neurol"},{"key":"4334_CR85","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1523\/JNEUROSCI.3096-13.2014","volume":"34","author":"AF Oliveira","year":"2014","unstructured":"Oliveira AF, Yasuda R. Neurofibromin is the major ras inactivator in dendritic spines. J Neurosci. 2014;34:776\u201383.","journal-title":"J Neurosci"},{"key":"4334_CR86","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3892\/etm.2021.11058","volume":"23","author":"F Nastase","year":"2022","unstructured":"Nastase F, Radaschin DS, Niculet E, Bradeanu AV, Verenca MC, Nechita A, et al. Orthopaedic manifestations of neurofibromatosis type 1: a case report. Exp Ther Med. 2022;23:135.","journal-title":"Exp Ther Med"},{"key":"4334_CR87","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.arcped.2022.05.007","volume":"29","author":"E Tekin","year":"2022","unstructured":"Tekin E. Bone deformities in patients with neurofibromatosis type 1: single-center experience. Arch Pediatr. 2022;29:434\u201338.","journal-title":"Arch Pediatr"},{"key":"4334_CR88","doi-asserted-by":"crossref","unstructured":"Stammers K, Cope S. Congenital pseudoarthrosis in a child with neurofibromatosis. BMJ Case Rep. 2015;2015.","DOI":"10.1136\/bcr-2015-212813"},{"key":"4334_CR89","doi-asserted-by":"publisher","first-page":"7","DOI":"10.13107\/jocr.2024.v14.i02.4198","volume":"14","author":"R Ambade","year":"2024","unstructured":"Ambade R, Malik S. Tibial dysplasia in neurofibromatosis-1: a rare case report and review of literature. J Orthop Case Rep. 2024;14:7\u201311.","journal-title":"J Orthop Case Rep"},{"key":"4334_CR90","doi-asserted-by":"crossref","unstructured":"Toro G, Santoro C, Ambrosio D, Landi G, Scilipoti M, Moretti A, et al. Natural history of scoliosis in children with NF1: an observation study. Healthcare (Basel). 2021;9.","DOI":"10.3390\/healthcare9070881"},{"key":"4334_CR91","doi-asserted-by":"publisher","first-page":"101172","DOI":"10.1016\/j.spen.2024.101172","volume":"52","author":"M Moodley","year":"2024","unstructured":"Moodley M, Lopez KR. Neurofibromatosis type 1 - an update. Semin Pediatr Neurol. 2024;52:101172.","journal-title":"Semin Pediatr Neurol"},{"key":"4334_CR92","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.5114\/aoms.2020.100309","volume":"16","author":"Y Wu","year":"2020","unstructured":"Wu Y, Cheng W, Zhang X, Li Z, Liu Y, Bai W. Neurofibromatosis type I-associated malignant peripheral nerve sheath tumors: a case report and literature review. Arch Med Sci. 2020;16:1476\u201382.","journal-title":"Arch Med Sci"},{"key":"4334_CR93","doi-asserted-by":"publisher","first-page":"594069","DOI":"10.3389\/fonc.2020.594069","volume":"10","author":"E Martin","year":"2020","unstructured":"Martin E, Acem I, Grunhagen DJ, Bovee J, Verhoef C. Prognostic significance of immunohistochemical markers and genetic alterations in malignant peripheral nerve sheath tumors: a systematic review. Front Oncol. 2020;10:594069.","journal-title":"Front Oncol"},{"key":"4334_CR94","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3324\/haematol.2009.010355","volume":"95","author":"D Steinemann","year":"2010","unstructured":"Steinemann D, Arning L, Praulich I, Stuhrmann M, Hasle H, Stary J, et al. Mitotic recombination and compound-heterozygous mutations are predominant NF1-inactivating mechanisms in children with juvenile myelomonocytic leukemia and neurofibromatosis type 1. Haematologica. 2010;95:320\u201323.","journal-title":"Haematologica"},{"key":"4334_CR95","doi-asserted-by":"publisher","first-page":"4314","DOI":"10.1182\/blood.V88.11.4314.bloodjournal88114314","volume":"88","author":"DK Miles","year":"1996","unstructured":"Miles DK, Freedman MH, Stephens K, Pallavicini M, Sievers EL, Weaver M, et al. Patterns of hematopoietic lineage involvement in children with neurofibromatosis type 1 and malignant myeloid disorders. Blood. 1996;88:4314\u201320.","journal-title":"Blood"},{"key":"4334_CR96","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1477-7819-8-14","volume":"8","author":"GN Zografos","year":"2010","unstructured":"Zografos GN, Vasiliadis GK, Zagouri F, Aggeli C, Korkolis D, Vogiaki S, et al. Pheochromocytoma associated with neurofibromatosis type 1: concepts and current trends. World J Surg Oncol. 2010;8:14.","journal-title":"World J Surg Oncol"},{"key":"4334_CR97","doi-asserted-by":"publisher","first-page":"792","DOI":"10.4158\/EP13417.OR","volume":"20","author":"MC Shinall","year":"2014","unstructured":"Shinall MC, Solorzano CC. Pheochromocytoma in neurofibromatosis type, 1: when should it be suspected? Endocr Pract. 2014;20:792\u201396.","journal-title":"Endocr Pract"},{"key":"4334_CR98","doi-asserted-by":"publisher","first-page":"111166","DOI":"10.1016\/j.ijscr.2025.111166","volume":"129","author":"A Ibrahimi","year":"2025","unstructured":"Ibrahimi A, Lachkar S, Boualaoui I, Sayegh HE, Nouini Y. Gastrointestinal stromal tumor in patient with neurofibromatosis type 1: a case report. Int J Surg Case Rep. 2025;129:111166.","journal-title":"Int J Surg Case Rep"},{"key":"4334_CR99","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1200\/JCO.2015.65.3576","volume":"34","author":"E Uusitalo","year":"2016","unstructured":"Uusitalo E, Rantanen M, Kallionpaa RA, Poyhonen M, Leppavirta J, Yla-Outinen H, et al. Distinctive Cancer associations in patients with neurofibromatosis type 1. J Clin Oncol. 2016;34:1978\u201386.","journal-title":"J Clin Oncol"},{"key":"4334_CR100","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/bjc.2016.403","volume":"116","author":"E Uusitalo","year":"2017","unstructured":"Uusitalo E, Kallionpaa RA, Kurki S, Rantanen M, Pitkaniemi J, Kronqvist P, et al. Breast cancer in neurofibromatosis type 1: overrepresentation of unfavourable prognostic factors. Br J Cancer. 2017;116:211\u201317.","journal-title":"Br J Cancer"},{"key":"4334_CR101","doi-asserted-by":"crossref","unstructured":"Jaber D, Zhang J, Godley LA. Detecting likely germline variants during tumor-based molecular profiling. J Clin Invest. 2025;135.","DOI":"10.1172\/JCI190264"},{"key":"4334_CR102","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.rpor.2020.04.010","volume":"25","author":"L Binobaid","year":"2020","unstructured":"Binobaid L, Masternak MM. Molecular targets for NF1-associated malignant peripheral nerve sheath tumor. Rep Pract Oncol Radiother. 2020;25:556\u201361.","journal-title":"Rep Pract Oncol Radiother"},{"key":"4334_CR103","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1093\/neuonc\/noz086","volume":"21","author":"S Suppiah","year":"2019","unstructured":"Suppiah S, Aldape K, Zadeh G. Needle in a haystack: identifying drivers of malignant transformation in neurofibromas. Neuro Oncol. 2019;21:961\u201362.","journal-title":"Neuro Oncol"},{"key":"4334_CR104","doi-asserted-by":"crossref","unstructured":"Legius E, Messiaen L, Wolkenstein P, Pancza P, Avery RA, Berman Y, et al. International Consensus Group on Neurofibromatosis Diagnostic, S.M. Husoz, D.G. Evans, and S.R. Plotkin, Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genet Med. 2021;23:1506\u201313.","DOI":"10.1038\/s41436-021-01170-5"},{"key":"4334_CR105","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1089\/gtmb.2014.0109","volume":"18","author":"R Maruoka","year":"2014","unstructured":"Maruoka R, Takenouchi T, Torii C, Shimizu A, Misu K, Higasa K, et al. The use of next-generation sequencing in molecular diagnosis of neurofibromatosis type 1: a validation study. Genet Test Mol Biomarker. 2014;18:722\u201335.","journal-title":"Genet Test Mol Biomarker"},{"key":"4334_CR106","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1007\/s12031-014-0286-7","volume":"53","author":"B Balla","year":"2014","unstructured":"Balla B, Arvai K, Horvath P, Tobias B, Takacs I, Nagy Z, et al. Fast and robust next-generation sequencing technique using ion torrent personal genome machine for the screening of neurofibromatosis type 1 (NF1) gene. J Mol Neurosci. 2014;53:204\u201310.","journal-title":"J Mol Neurosci"},{"key":"4334_CR107","doi-asserted-by":"publisher","first-page":"603195","DOI":"10.3389\/fgene.2021.603195","volume":"12","author":"ZY Zhang","year":"2021","unstructured":"Zhang ZY, Wu YY, Cai XY, Fang WL, Xiao FL. Molecular diagnosis of neurofibromatosis by multigene panel testing. Front Genet. 2021;12:603195.","journal-title":"Front Genet"},{"key":"4334_CR108","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jmoldx.2010.09.002","volume":"13","author":"MC Valero","year":"2011","unstructured":"Valero MC, Martin Y, Hernandez-Imaz E, Hernandez AM, Melean G, Valero AM, et al. A highly sensitive genetic protocol to detect NF1 mutations. J Mol Diagn. 2011;13:113\u201322.","journal-title":"J Mol Diagn"},{"key":"4334_CR109","doi-asserted-by":"publisher","first-page":"11291","DOI":"10.1038\/srep11291","volume":"5","author":"J Zhang","year":"2015","unstructured":"Zhang J, Tong H, Fu X, Zhang Y, Liu J, Cheng R, et al. Molecular characterization of NF1 and neurofibromatosis type 1 genotype-phenotype correlations in a Chinese population. Sci Rep. 2015;5:11291.","journal-title":"Sci Rep"},{"key":"4334_CR110","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41525-021-00258-w","volume":"6","author":"R Koster","year":"2021","unstructured":"Koster R, Brandao RD, Tserpelis D, van Roozendaal CEP, van Oosterhoud CN, Claes KBM, et al. Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq. NPJ Genom Med. 2021;6:95.","journal-title":"NPJ Genom Med"},{"key":"4334_CR111","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1002\/humu.24487","volume":"43","author":"HCW Douben","year":"2022","unstructured":"Douben HCW, Nellist M, van Unen L, Elfferich P, Kasteleijn E, Hoogeveen-Westerveld M, et al. High-yield identification of pathogenic NF1 variants by skin fibroblast transcriptome screening after apparently normal diagnostic DNA testing. Hum Mutat. 2022;43:2130\u201340.","journal-title":"Hum Mutat"},{"key":"4334_CR112","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.ebiom.2016.04.005","volume":"7","author":"DG Evans","year":"2016","unstructured":"Evans DG, Bowers N, Burkitt-Wright E, Miles E, Garg S, Scott-Kitching V, et al. Comprehensive RNA analysis of the NF1 gene in classically affected NF1 affected individuals meeting NIH criteria has high sensitivity and mutation negative testing is reassuring in isolated cases with pigmentary features only. EBioMedicine. 2016;7:212\u201320.","journal-title":"EBioMedicine"},{"key":"4334_CR113","doi-asserted-by":"publisher","first-page":"9386823","DOI":"10.1155\/2021\/9386823","volume":"2021","author":"DK Knewitz","year":"2021","unstructured":"Knewitz DK, Anderson CJ, Presley WT, Horodyski M, Scarborough MT, Wallace MR. Survival and NF1 analysis in a cohort of orthopedics patients with malignant peripheral nerve sheath tumors. Sarcoma. 2021;2021:9386823.","journal-title":"Sarcoma"},{"key":"4334_CR114","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/s41431-021-01015-4","volume":"30","author":"C Forde","year":"2022","unstructured":"Forde C, Burkitt-Wright E, Turnpenny PD, Haan E, Ealing J, Mansour S, et al. Natural history of NF1 c.2970_2972del p.(Met992del): confirmation of a low risk of complications in a longitudinal study. Eur J Hum Genet. 2022;30:291\u201397.","journal-title":"Eur J Hum Genet"},{"key":"4334_CR115","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1097\/CM9.0000000000003203","volume":"137","author":"B Zhu","year":"2024","unstructured":"Zhu B, Wang W, Gu Y, Wei C, Wang Z, Li Q. Genotype-phenotype correlations and treatment innovation of neurofibromatosis type 1 (NF1): current understanding and perspective. Chin Med J (Engl). 2024;137:1639\u201341.","journal-title":"Chin Med J (Engl)"},{"key":"4334_CR116","doi-asserted-by":"publisher","first-page":"4142","DOI":"10.1158\/1078-0432.CCR-20-5032","volume":"27","author":"D Casey","year":"2021","unstructured":"Casey D, Demko S, Sinha A, Mishra-Kalyani PS, Shen YL, Khasar S, et al. FDA Approval Summary: Selumetinib for Plexiform Neurofibroma. Clin Cancer Res. 2021;27:4142\u201346.","journal-title":"Clin Cancer Res"},{"key":"4334_CR117","unstructured":"FDA approves selumetinib for neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas, 2025."},{"key":"4334_CR118","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1093\/neuonc\/noac109","volume":"24","author":"AM Gross","year":"2022","unstructured":"Gross AM, Glassberg B, Wolters PL, Dombi E, Baldwin A, Fisher MJ, et al. Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity. Neuro Oncol. 2022;24:1978\u201388.","journal-title":"Neuro Oncol"},{"key":"4334_CR119","doi-asserted-by":"publisher","first-page":"877","DOI":"10.2217\/fon-2023-0565","volume":"20","author":"AM Gross","year":"2024","unstructured":"Gross AM, Achee C, Hart SE, Brewer L, Baldwin A, Wolters PL, et al. Selumetinib for children with neurofibromatosis type 1 and plexiform neurofibromas: a plain language summary of SPRINT. Future Oncol. 2024;20:877\u201390.","journal-title":"Future Oncol"},{"key":"4334_CR120","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1016\/S0140-6736(25)00986-9","volume":"405","author":"AP Chen","year":"2025","unstructured":"Chen AP, Coyne GO, Wolters PL, Martin S, Farschtschi S, Blanco I, et al. Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study. Lancet. 2025;405:2217\u201330.","journal-title":"Lancet"},{"key":"4334_CR121","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1200\/JCO.24.01034","volume":"43","author":"CL Moertel","year":"2025","unstructured":"Moertel CL, Hirbe AC, Shuhaiber HH, Bielamowicz K, Sidhu A, Viskochil D, et al. ReNeu Trial, and I. ReNeu study, ReNeu: a pivotal, phase IIb Trial of Mirdametinib in adults and children with symptomatic neurofibromatosis type 1-associated plexiform neurofibroma. J Clin Oncol. 2025;43:716\u201329.","journal-title":"J Clin Oncol"},{"key":"4334_CR122","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1016\/S0140-6736(25)01155-9","volume":"405","author":"CG Romo","year":"2025","unstructured":"Romo CG, Pratilas CA. KOMET in the landscape of MEK inhibitor clinical trials for plexiform neurofibromas. Lancet. 2025;405:2182\u201384.","journal-title":"Lancet"},{"key":"4334_CR123","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1080\/13543784.2025.2558656","volume":"34","author":"G Oztosun","year":"2025","unstructured":"Oztosun G, Armstrong A, Hirbe AC. Mirdametinib, an FDA-Approved MEK1\/2 inhibitor for adult and pediatric NF1-associated plexiform neurofibromas. Expert Opin Investig Drugs. 2025;34:665\u201373.","journal-title":"Expert Opin Investig Drugs"},{"key":"4334_CR124","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1002\/ajmg.a.37045","volume":"167","author":"VM Riccardi","year":"2015","unstructured":"Riccardi VM. Ketotifen suppression of NF1 neurofibroma growth over 30 years. Am J Med Genet A. 2015;167:1570\u201377.","journal-title":"Am J Med Genet A"},{"key":"4334_CR125","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1590\/abd1806-4841.20132125","volume":"88","author":"JR Antonio","year":"2013","unstructured":"Antonio JR, Goloni-Bertollo EM, Tridico LA. Neurofibromatosis: chronological history and current issues. An Bras Dermatol. 2013;88:329\u201343.","journal-title":"An Bras Dermatol"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04334-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04334-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04334-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T10:05:21Z","timestamp":1778580321000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04334-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":125,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4334"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04334-1","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"assertion":[{"value":"16 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"189"}}